Merck Ranks 68th in Trading Volume with $10.92 Billion as Stock Price Rises 0.30

On June 27, 2025, Merck & Co., Inc. (MRK) saw a trading volume of $10.92 billion, ranking 68th in the day's stock market activity. The company's stock price increased by 0.30%.

Merck's recent financial performance has been robust, with strong growth reflected in its Q4 and full-year 2024 results. The company reported significant worldwide sales, highlighting its continued success in the pharmaceutical industry.

In terms of product development, Merck has made several notable advancements. The company announced that the Phase 3 HYPERION study of WINREVAIR™ (sotatercept-csrk) met its primary endpoint in recently diagnosed adults with Pulmonary Arterial Hypertension (PAH). Additionally, the IDeate-Prostate01 Phase 3 trial of Ifinatamab Deruxtecan was initiated for patients with pretreated metastatic castration-resistant prostate cancer.

Merck also received regulatory approvals and positive opinions for several of its products. The FDA approved KEYTRUDA® (pembrolizumab) for PD-L1+ resectable locally advanced head & neck squamous cell carcinoma as neoadjuvant treatment, continued as adjuvant treatment combined with radiotherapy with or without cisplatin, then as a single agent. Merck Animal Health received a positive opinion from the EU CVMP for NUMELVI™ (atinvicitinib) tablets for dogs.

Furthermore, Merck is expanding its innovative internal generative AI solutions to help deliver medicines to patients faster. The company is also focusing on advancing equity in cardiac care across the U.S. through the Merck Foundation.